Diffuse parenchymal lung diseases (DPLDs) are a group of more than 200 diverse chronic pulmonary disorders characterized by progressive fibrosis leading to destruction of lung architecture resulting in respiratory failure and finally death. Being mostly non-specific, distinguishing between different DPLDs is difficult. The classification is often based on differences in etiology with IPF being the most common of DPLDs of unknown origin and chronic HP is an important representative for DPLDs of known cause.\[[@ref1]\]

Both IPF and chronic HP lead to end-stage pulmonary fibrosis with excessive collagen deposition, extracellular matrix deposition, and destruction of lung architecture, leading to respiratory failure.\[[@ref2]\] Although they share similarities in clinical presentation, prognosis and treatment are different, indicating the importance to differentiate between these disorders for which BAL may be used.\[[@ref3][@ref4]\]

The pathophysiological mechanism of HP is accepted to be a hypersensitivity reaction, induced by a T-cell-mediated reaction after sensitization with antigens such as organic dusts, bacteria, and molds,\[[@ref5]\] but the exact mechanisms are unresolved. Despite intensive research, the pathophysiological mechanisms of IPF remain enigmatic. Complicating factors are (1) the majority of current knowledge is based on the mouse model of bleomycin-induced fibrosis, which is an useful model but not specific for IPF, (2) the late diagnosis of IPF precludes the ability to study early mechanisms and etiology, (3) the discrepancy between clinical, histological, and radiological findings for diagnosis, and (4) the scarcity of the disease.

In the pathogenesis of pulmonary fibrosis, many contributing mechanisms have been described, including angiogenesis, coagulation, fibrogenesis, tissue repair, inflammation, epithelial damage, matrix remodeling, and oxidative stress. As both disorders progress toward end-stage parenchymal lung fibrosis, an important question is whether similar mechanisms drive this fibrosis. BAL represents the closest sampling tool of the lung besides biopsies and the earliest time point possible to research these disorders. Therefore, our aim was to study the differences and similarities in mechanistic pathways involved in IPF and chronic HP using BAL fluid. For this study, we focused on 25 proteins related to different mechanisms using multiplex SearchLight^®^ Assay System. Its use helps to provide new information to unravel mechanisms triggering pulmonary fibrosis.\[[@ref3]\]

Methods {#sec1-1}
=======

Study design {#sec2-1}
------------

This study was approved by the Ethics Committee (S51293) and Biosafety (MS20101568) of the University Hospital UZ Leuven, Belgium. At the time of diagnosis, patients underwent spirometry tests and bronchoscopy with BAL as part of the diagnostic work-up. The total lung capacity (TLC), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV~1~), and diffusing capacity (DL~CO~) were measured according to international guidelines.\[[@ref6]\] During bronchoscopic evaluation, BAL was performed following standard guidelines.\[[@ref7][@ref8]\] BAL consisted of four aliquots of sterile saline (50 ml) instilled in the right middle lobe or lingula; returned fraction 1 was used for microbiological evaluation, fractions 2, 3 and 4 were pooled and used to assess cellular differentiation, BAL return and protein analysis.\[[@ref9]\]

After multidisciplinary consultation, patients with IPF (*n* = 11) and HP (*n* = 11) were selected and compared with a control group (*n* = 10) without evidence for a pulmonary disease. BAL samples were analyzed by means of multiplex searchlight technology to unravel different pathological mechanisms.

Patient selection {#sec2-2}
-----------------

Patients were diagnosed within a multidisciplinary consensus as suggested by international guidelines. IPF patient diagnosis was based on clinical, radiological, and/or pathological data following international guidelines.\[[@ref10]\] Patients were diagnosed with chronic HP based on their clinical course and insidious onset over a period of months, history of antigen exposure, radiological, and/or histopathological data.\[[@ref11][@ref12]\] Both disorders showed the presence of fibrosis in radiological data. For the control group, history was recorded and BAL, biopsy, and radiological imaging were performed to exclude pulmonary illness/fibrosis (e.g., esophageal cancer, connective tissue disease without pulmonary affection). Medical history provided information regarding age, gender, and smoking history (pack years and amount of current-/ex-/non-smokers). Plasma C-reactive protein (CRP) levels were measured to assess systemic inflammation.\[[@ref13]\] The selection was refined by excluding patients with lack of clinical data, no full pulmonary function data, lack of sufficient BAL sample, and highly increased CRP levels (\>20 mg/l). Finally, 10 controls, 11 IPF, and 11 HP patients were included.

Bronchoalveolar lavage protein measurement {#sec2-3}
------------------------------------------

Protein expression was analyzed in undiluted or 1:10 diluted BAL supernatant using the custom multiplex SearchLight^®^ Assay System (Aushon, Billerica, MA, USA). Twenty-five proteins based on the different pathophysiological mechanisms were selected: Eotaxin, basic fibroblast growth factor (FGFb), fibronectin, HGF, IL-8, IL-12p40, IL-17, IL-23, MCP-1, MDC, MPO, MMP-8, MMP-9, active PAI-1, PARC, PlGF, Protein-C, RAGE, RANTES, SP-C, TGF-β1, TIMP-1, tissue factor, TSLP, and VEGF (for abbreviations, see [Table 1](#T1){ref-type="table"}). If concentration was below detection limit, a value of 50% of the detection limit was attributed (detection limits: FGFb = 2.0 pg/ml; IL-12p40 = 0.6 pg/ml; IL-17 = 0.8 pg/ml; IL-23 = 19.5 pg/ml; RANTES = 0.4 pg/ml; SP-C = 65.4 pg/ml; TGF-β1 = 19.5 pg/ml; and TSLP = 2.4 pg/ml).

###### 

Abbreviations for factors analyzed in bronchoalveolar lavage fluid
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Analysis {#sec2-4}
--------

Results are expressed as median (interquartile range \[IQR\]). Significances among the groups were tested by Kruskal--Wallis one-way analysis of variance (ANOVA) in combination with Mann--Whitney *U* test. Correlation analysis using the Spearman rank test was performed on both HP and control and on both the IPF and control. Statistical analysis was performed using Prism 4.1 software (GraphPad, San Diego, CA, USA). Results were considered significant if *P* \< 0.05.

Results {#sec1-2}
=======

Patient characteristics {#sec2-5}
-----------------------

Patient characteristics are summarized in [Table 2](#T2){ref-type="table"}. No significant differences were observed for age, sex, smoking history, plasma CRP level, or BAL return fraction between the control, IPF, and HP groups.

###### 

Patient characteristics
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Pulmonary function and bronchoalveolar lavage cell differentiation {#sec2-6}
------------------------------------------------------------------

Pulmonary function measurements are described in [Table 2](#T2){ref-type="table"} and BAL cell differentiation in [Table 3](#T3){ref-type="table"}. Both IPF and HP patients showed significant decrease in pulmonary function parameters (TLC, FVC, FEV~1~, and DL~CO~) compared with the control group. No differences were found between IPF and HP patients.

###### 

Cellular differentiation of bronchoalveolar lavage fluid

![](ATM-8-38-g003)

In IPF, an increase in percentage and total number of neutrophils (*P* = 0.0025; *P* = 0.0017) and eosinophils (*P* = 0.0002; *P* = 0.0002) was observed compared with the control group.

In HP, total white blood cell number was significantly increased compared with the control group (*P* = 0.0067). The number of macrophages did not change but a decrease in their percentage (*P* = 0.0167) was observed. An increase in percentage and total number of lymphocytes (*P* = 0.0412; *P* = 0.0067), neutrophils (*P* = 0.0017; *P* = 0.0008), and eosinophils (*P* = 0.0002; *P* = 0.0002) was observed compared with control.

When comparing IPF with HP, an increase in percentage of lymphocytes (*P* = 0.00216) was observed in HP.

Bronchoalveolar lavage protein measurement {#sec2-7}
------------------------------------------

Protein measurements are summarized in [Table 4](#T4){ref-type="table"}. ANOVA statistics were not significant for RAGE, SP-C, TIMP-1, fibronectin, eotaxin, IL-17A, IL-23, PARC, RANTES, TSLP, PlGF, FGFb, and tissue factor and will therefore not be further discussed.

###### 

Protein profile in bronchoalveolar lavage fluid
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When compared with the control group, an increase in MMP-8 (*P* = 0.038; *P* = 0.0083), MMP-9 (*P* = 0.010; *P* = 0.0006), MCP-1 (*P* = 0.0011; *P* = 0.0014), MDC (*P* = 0.0044; *P* = 0.018), IL-8 (*P* = 0.018; *P* = 0.0083), MPO (*P* = 0.015; *P* = 0.022), and Protein-C (*P* = 0.045; *P* = 0.0054) was observed, whereas VEGF was decreased (*P* = 0.0014; *P* = 0.0005) in both disorders.

In IPF, active PAI-1 was increased (*P* = 0.0022), a trend toward increase for HGF (*P* = 0.053) and a decrease for IL-12p40 (*P* = 0.072) was found compared with control.

In HP, compared with control, HGF was significantly upregulated (*P* = 0.0022) and a trend toward increase for active PAI-1 (*P* = 0.091) and decrease for TGF-β1 (*P* = 0.057) was found.

In HP, compared with IPF, TGF-β1 (*P* = 0.0045) was decreased and IL-12p40 (*P* = 0.072) was increased.

Correlation analysis {#sec2-8}
--------------------

Correlation results are summarized in [Table 5](#T5){ref-type="table"}. Regarding IPF, there was a significant correlation between DL~CO~ and BAL protein expression of HGF (*R* = --0.49; *P* = 0.023), MCP-1 (*R* = --0.47; *P* = 0.030), MDC (*R* = --0.58; *P* = 0.0064), IL-8 (*R* = --0.45; *P* = 0.040), IL-12p40 (*R* = 0.50; *P* = 0.020), VEGF (*R* = 0.60; *P* = 0.0039), Protein-C (*R* = --0.50; *P* = 0.022), and active PAI-1 (*R* = --0.49; *P* = 0.024). In addition, a correlation was found between FVC and MDC (*R* = --0.48; *P* = 0.029), IL-8 (*R* = --0.47; *P* = 0.031), VEGF (*R* = 0.56; *P* = 0.0087), and Protein-C (*R* = --0.67; *P* = 0.0008).

###### 

Correlation analysis of bronchoalveolar lavage protein expression with pulmonary function
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In patients with HP, there was a significant correlation between DL~CO~ and TGF-β1 (*R* = 0.55; *P* = 0.010), MCP-1 (*R* = --0.58; *P* = 0.0062), IL-8 (*R* = --0.47; *P* = 0.030), and VEGF (*R* = 0.72; *P* = 0.0002). Additionally, there was a significant correlation between FVC and MMP-9 (*R* = --0.44; *P* = 0.049), IL-8 (*R* = --0.60; *P* = 0.0042), and VEGF (*R* = 0.51; *P* = 0.018).

Discussion {#sec1-3}
==========

In this study, we examined the involvement of different pathophysiological mechanisms in BAL in IPF and HP, using multiplex protein analysis of 25 different proteins. In both IPF and HP, we observed differences in key factors of angiogenesis (VEGF), coagulation (protein-C and active PAI-1), fibrogenesis (TGF-β1), tissue repair (HGF), inflammation (MCP-1, MDC, and IL-8), matrix remodeling (MMP-8 and MMP-9), and oxidative stress (MPO). Patients with IPF or HP demonstrated decreased pulmonary function combined with altered differential cell counts of BAL. Although IPF and HP differ in onset and clinical presentation, only a few significant differences between them were found.

The first observation in the well-characterized groups was that BAL cellular pattern in both disorders was different, as patients with HP suffer from lymphocytic inflammation compared with IPF and control. This might suggest a discriminative role for BAL in diagnosis of IPF and HP.

The role of innate immunity in IPF and HP has been shown by the upregulation of MCP-1 and MDC. MCP-1, involved in macrophage recruitment, was negatively correlated with DL~CO~ for IPF and HP.\[[@ref14][@ref15]\] Suga *et al*. investigated MCP-1 in HP and found no increase in its expression. This difference might be due to the high lymphocytosis (average \> 70%) found in their patients.\[[@ref13]\] Alternatively, this can be explained by a higher number of patients with acute HP in comparison with our study. In seasonal summer-type HP, an increase in MCP-1 was interpreted as a possible causative mechanism following repeated stimulations.\[[@ref16]\] MDC was negatively correlated with DL~CO~ and FVC in IPF and negatively correlated with DL~CO~ in HP. MDC contributes to pulmonary fibrosis by recruiting macrophages and triggering T-helper cell 2 inflammation, further inducing fibrogenic proteins by stimulating macrophages.\[[@ref17]\]

IL-8 functions as a major chemoattractant for neutrophils and has a role in angiogenesis.\[[@ref18]\] In both IPF and HP, IL-8 was significantly upregulated and correlated negatively with DL~CO~ and FVC. Neutrophil numbers and percentages were increased in both disorders, indicating an important role for IL-8 as neutrophil attractant. IL-8 has been proposed as an early phase marker for IPF and an indicator of continuous exposure to provoking agents for HP.\[[@ref19]\]

MPO expression, a marker for oxidative stress produced by neutrophils, was increased in IPF and HP, corroborating with literature.\[[@ref20]\] A shift in the redox balance of IPF has been demonstrated to favor oxidants involving an IL-8-dependent mechanism.\[[@ref21]\] In addition, increased levels of MMP-8 and MMP-9, expressed by neutrophils, were found without a compensatory increase in TIMP-1 in both disorders, corroborating the findings of Henry *et al*.\[[@ref22][@ref23]\] This imbalance enhances the activity of MMPs influencing remodeling and development of fibrosis.

Despite current issues on BAL and neutrophils, we observed an important role for immunological mechanisms including neutrophilia and associated oxidative stress and matrix remodeling, in perpetuating both disorders. The activation of the innate arm of the immune system can be linked with reflux,\[[@ref24]\] Pseudomonas colonization,\[[@ref25]\] and air pollution.\[[@ref26]\] Although there is no direct proof for the involvement of innate activation and its different activators, our results might point to a certain role in the process. We recently demonstrated in lung transplant patients that traffic-related air pollution can cause substantial airway immunological reactions with an increase in mortality. Yet very importantly, it was observed that macrolide therapy was protective for this immunological reaction and related development of chronic rejection and mortality. With the studied disorders, HP and IPF, showing similar mechanisms regarding innate immunity in chronic rejection after lung transplantation, one should consider decreasing the innate immune response. In this regard, as in chronic rejection, a potential agent might be the macrolide azithromycin, which was recently studied in the bleomycin mouse model where it modulated both innate and adaptive immunity and consequently reduced parenchymal fibrosis.\[[@ref27]\]

Previous studies have shown an increased ratio of angiogenic and angiostatic chemokines in BAL of IPF and HP patients, indicating upregulation of angiogenesis.\[[@ref28][@ref29]\] In this study, we observed a downregulation of VEGF in IPF and HP. It has been suggested that VEGF is increased in non-fibrotic, more inflammatory regions and decreased in severe fibrosis.\[[@ref30][@ref31]\] This decrease of VEGF at the site of fibrosis may be mediated by proteolytic degradation or may result from epithelial cell apoptosis or injury.\[[@ref32]\] Thickening of the barrier between the epithelial surface and the intravascular space due to fibrosis may alter the secretion of VEGF. This also suggests the reason for positive correlation of VEGF with DL~CO~ and FVC in both disorders.\[[@ref33]\]

Protein-C was upregulated in both disorders and when activated, it has shown a potential anti-fibrotic effect by diminishing inflammation and coagulation.\[[@ref34][@ref35]\] This increased expression was remarkably higher in patients with HP compared with IPF. This is in agreement with literature where protein-C has shown to be increased in IPF, but its activated form was decreased.\[[@ref36]\] Enhanced plasminogen activity provides an environment supporting tissue repair in the lung by increasing levels of active HGF. We are the first to report an upregulation of HGF in HP. HGF stimulates the proliferation of alveolar type II epithelial cells and inhibits epithelial to myofibroblast transition.\[[@ref37][@ref38]\] It has been shown that production and activation of HGF are reduced in fibroblasts in IPF secondary to a defect in prostaglandin E2 secretion.\[[@ref39]\] The expression of HGF may also be restrained by the anti-fibrinolytic effect of PAI-1, which was upregulated and correlated with DL~CO~ in patients with IPF, as shown in literature.\[[@ref40]\] These data show that the role of the coagulation pathway may be different between IPF and chronic HP. The enhanced plasminogen activity may provide an environment explaining a slower progression of pulmonary fibrosis in chronic HP when compared to IPF.

Apart from similarities, significant differences between IPF and HP were also found. IL-12p40 was upregulated in HP compared with IPF. IL-12p40 directs the immune response toward the appropriate location and correct pathogen.\[[@ref41]\] This points toward the role of the hypersensitivity reaction present in patients with HP.\[[@ref42]\] TGF-β1, known as the fibrotic molecule in IPF and experimental fibrosis, was not significantly different in both disorders when compared with control,\[[@ref43]\] due to large variance in samples. A significant decrease in patients with HP compared with IPF was observed. This difference between IPF and HP has been documented previously by Hagimoto *et al*.\[[@ref44]\] The increase in TGF-β1 is thought to be produced by alveolar macrophages, in an early inflammatory phase and by epithelial cells during the later fibrotic phase.\[[@ref45]\] This could explain the lower concentration of TGF-β1 in HP as they are in a chronic phase of the disorder, with less fibrosis than in IPF.

VEGF (angiogenesis), IL-8, MCP-1, MDC, IL-12p40 (inflammation), HGF (tissue repair), TGF-β1 (fibrogenesis), MMP-9 (matrix remodeling), protein-C, and active PAI-1 (coagulation) were correlated with DL~CO~ and/or FVC for IPF and HP, reflecting the degree of severity. This indeed suggests that pulmonary fibrosis is the result of a combination of different pathological mechanisms.

The major limitation of this study is the low number of samples that were used. Both IPF and HP are orphan diseases and to establish homogenous groups well-documented cases are needed. We are convinced that with higher number of patients, the results would be more pronounced and might have less variability. BAL sampling was performed at the time of diagnosis, potentially reflecting different stages of pulmonary fibrosis, which might explain the broad range of protein expression in each group \[[Figure 1](#F1){ref-type="fig"}\]. However, time of diagnosis presents the earliest possible phase for BAL sampling in the clinic. This study confirms the usefulness of BAL for research purposes uncovering similarities and differences between these disorders.

![The expression of (a) active PAI-1, (b) TGF-β1, (c) IL-8, and (d) HGF shown as median with IQR (for Abbreviations, see [Table 1](#T1){ref-type="table"}) in BAL fluid of 10 controls, 11 IPF, and 11 HP patients. Significances: \**P*\<0.05, \*\**P*\<0.01 remove:, and \*\*\**P*\<0.001](ATM-8-38-g006){#F1}

This research provides a better understanding of the involvement of underlying mechanisms and differences between these diseases are compared with the use of animal models. This study demonstrates that though common mechanisms appear, some mechanistic discrepancies were discovered, providing new clues for further research in both disorders.
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